Monday's Health Winners & Losers
The Food and Drug Administration gave Pfizer's (PFE) HIV drug its blessing Monday while rumors of good data lifted another health stock.
The FDA granted accelerated approval to Pfizer's Selzentry tablets for HIV based on 24-week data. The drug is the first in a class (called CCR5 antagonists) that stop the R5 virus on the outside surface of cells before it enters, rather than fighting the virus inside as do all other classes of oral HIV medicines, according the company.
"The approval of Selzentry for treatment-experienced patients is a significant breakthrough, and we continue its development in a spectrum of other patients living with HIV/AIDS," said Joseph Feczko, Pfizer's chief medical officer. Selzentry is expected to be available in the U.S. by the middle of September. The company recently received a positive opinion from the Committee for Medicinal Products for Human Use in the EU, and plans to commercialize it as Celsentri outside of the U.S. The stock was up 54 cents, or 2.3%, at $24.05.
Vertex Pharmaceuticals (VRTX) gained $2.92, or 8.8%, to $36.14 after analysts at Leerink Swann & Co. issued a note indicating a favorable outlook for interim data from the PROVE-1 study of Telaprevir in Hepatitis C patients. The analysts also said that management comments suggest the key clinical data from PROVE-1 will be presented at the American Association for the Study of Liver Diseases meeting in November and not the Interscience Conference on Antimicrobial Agents and Chemotherapy in September.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV